Neuroone Historical Cash Flow
| NMTC Stock | USD 0.68 0.02 2.86% |
Analysis of Neuroone Medical cash flow over time is an excellent tool to project Neuroone Medical Tec future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 9.9 M or Total Cash From Financing Activities of 8.9 M as it is a great indicator of Neuroone Medical ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Neuroone Medical Tec latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Neuroone Medical Tec is a good buy for the upcoming year.
Neuroone |
About Neuroone Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Neuroone balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Neuroone's non-liquid assets can be easily converted into cash.
Neuroone Medical Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Neuroone Medical's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Neuroone Medical Tec current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuroone Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At present, Neuroone Medical's End Period Cash Flow is projected to increase significantly based on the last few years of reporting. The current year's Begin Period Cash Flow is expected to grow to about 9.9 M, whereas Change In Cash is projected to grow to (3.1 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Begin Period Cash Flow | 6.9M | 8.2M | 9.4M | 9.9M | End Period Cash Flow | 8.2M | 5.3M | 6.1M | 6.4M |
Neuroone Medical cash flow statement Correlations
Click cells to compare fundamentals
Neuroone Medical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Neuroone Medical cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 3.8M | 2.9M | 1.3M | (2.8M) | (3.3M) | (3.1M) | |
| Free Cash Flow | (3.5M) | (8.7M) | (7.8M) | (13.3M) | (11.9M) | (11.3M) | |
| Change In Working Capital | (429.6K) | (512.7K) | 1.2M | (2.4M) | (2.2M) | (2.1M) | |
| Other Non Cash Items | 6.7M | 69.4K | 212.2K | 109.8K | 126.3K | 120.0K | |
| Capital Expenditures | 122.4K | 67.1K | 275.2K | 384.1K | 441.7K | 463.8K | |
| Total Cash From Operating Activities | (3.4M) | (8.6M) | (7.5M) | (12.9M) | (11.6M) | (11.0M) | |
| End Period Cash Flow | 4.0M | 6.9M | 8.2M | 5.3M | 6.1M | 6.4M | |
| Begin Period Cash Flow | 260.7K | 4.0M | 6.9M | 8.2M | 9.4M | 9.9M | |
| Other Cashflows From Financing Activities | (1.5M) | 2.7M | (1.3M) | (1.1M) | (964.5K) | (916.3K) | |
| Net Income | (13.6M) | (9.9M) | (10.0M) | (11.9M) | (10.7M) | (10.1M) | |
| Total Cash From Financing Activities | 7.3M | 11.5M | 12.0M | 7.4M | 8.5M | 8.9M | |
| Investments | (122.4K) | (67.1K) | (3.2M) | 2.6M | 3.0M | 3.2M | |
| Total Cashflows From Investing Activities | (123.4K) | (122.4K) | (67.1K) | (3.2M) | (2.9M) | (2.8M) | |
| Depreciation | 47.6K | 80.7K | 118.6K | 199.3K | 229.2K | 240.6K | |
| Change To Operating Activities | (872.5K) | (160.0K) | (15.8K) | 1.3M | 1.5M | 1.6M | |
| Change To Netincome | 1.2M | 8.7M | 1.8M | 1.1M | 1.3M | 2.2M | |
| Change To Liabilities | 770.6K | (269.6K) | (350.3K) | 515.4K | 592.8K | 622.4K | |
| Stock Based Compensation | 1.8M | 1.8M | 947.2K | 1.1M | 1.3M | 1.1M | |
| Issuance Of Capital Stock | 390K | 8.8M | 13.4M | 8.6M | 9.9M | 7.9M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neuroone Medical Tec offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neuroone Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neuroone Medical Technologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neuroone Medical Technologies Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuroone Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuroone Medical. If investors know Neuroone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuroone Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.48) | Revenue Per Share 0.158 | Quarterly Revenue Growth 0.311 | Return On Assets (1.43) | Return On Equity (3.49) |
The market value of Neuroone Medical Tec is measured differently than its book value, which is the value of Neuroone that is recorded on the company's balance sheet. Investors also form their own opinion of Neuroone Medical's value that differs from its market value or its book value, called intrinsic value, which is Neuroone Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuroone Medical's market value can be influenced by many factors that don't directly affect Neuroone Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuroone Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuroone Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuroone Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.